Michelle Casto
Adult Health · Palatka, FLNPI 1578937843
Payments from drug & device makers
Across 281 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AbbVie$591
- Novo Nordisk$533
- AstraZeneca$516
- Bayer$149
- Sanofi-aventis U.S. LLC$141
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,453100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 98 | $1,299 |
| AbbVie | 38 | $591 |
| Novo Nordisk | 38 | $533 |
| AstraZeneca | 24 | $516 |
| Bayer | 8 | $149 |
| Sanofi-aventis U.S. LLC | 8 | $141 |
| GSK | 7 | $126 |
| Merck | 7 | $119 |
| Pfizer | 6 | $107 |
| Mylan Specialty L.p. | 4 | $93 |
| Idorsia Pharmaceuticals US Inc | 5 | $91 |
| Otsuka America Pharmaceutical, Inc. | 4 | $90 |
| Exact Sciences | 4 | $69 |
| Corcept Therapeutics | 3 | $65 |
| Genentech USA, Inc. | 3 | $53 |
| Astellas Pharma US Inc | 3 | $50 |
| Radius Health, Inc. | 2 | $42 |
| Dexcom, Inc. | 3 | $39 |
| Pulmonx Corporation | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| Eisai Inc. | 2 | $27 |
| Catalyst Pharmaceuticals, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Boehringer Ingelheim | 2 | $23 |
| Amarin Pharma, Inc. | 1 | $23 |
| Corium, LLC | 1 | $19 |
| Insulet Corporation | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,453 in reported general payments places this provider in the 90th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 127 | $173,661 |
| JardianceEmpagliflozin | 144 | $132,959 |
| OzempicSemaglutide | 108 | $127,587 |
| EliquisApixaban | 67 | $60,454 |
| FarxigaDapagliflozin Propanediol | 73 | $57,829 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $42,744 |
| RexultiBrexpiprazole | 21 | $34,506 |
| MyrbetriqMirabegron | 40 | $33,337 |
| TradjentaLinagliptin | 21 | $26,897 |
| MounjaroTirzepatide | 18 | $24,602 |
| UbrelvyUbrogepant | 12 | $19,945 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $19,913 |
| XareltoRivaroxaban | 21 | $17,590 |
| LinzessLinaclotide | 30 | $15,483 |
| EntrestoSacubitril/Valsartan | 20 | $14,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,299 | $198,264145 claims |
| Boehringer IngelheimJardiance, Tradjenta | $23 | $159,856165 claims |
| Novo NordiskOzempic | $533 | $127,587108 claims |
| AstraZenecaFarxiga, Symbicort | $516 | $71,440114 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $126 | $62,65785 claims |
| PfizerEliquis | $107 | $60,45467 claims |
| AbbVieUbrelvy, Linzess | $591 | $35,42942 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $90 | $34,50621 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $33,33740 claims |
| Sanofi-aventis U.S. LLCMultaq | $141 | $9,05611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,237 adult health providers in Florida.
Other adult health in Palatka
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
- Cynthia OteroMaitland$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.